NCT07162441RecruitingPhase 1
A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers
Korea United Pharm. Inc.1 site in 1 country50 target enrollmentStarted: August 12, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Korea United Pharm. Inc.
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- AUCτ
Study Overview
Brief Summary
This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects aged 19 years or older at the time of screening.
- •Subjects with a body weight greater than 50 kg (≥45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg/m² at screening.
- •(BMI (kg/m²) = weight (kg) / height (m)²)
- •Subjects with no clinically significant congenital or chronic diseases, pathological symptoms or findings at screening.
- •Subjects determined by the principal investigator to be suitable for diagnostic procedures and electrocardiogram assessments
- •Subjects who agree to use an effective method of contraception (excluding hormonal agents) recognized as appropriate in clinical trials from the first administration of the investigational drug until 14 days after the last administration, together with their spouse or partner.
- •Subjects who have provided written informed consent after receiving a full explanation and demonstrating an understanding of the purpose, procedures, and characteristics of this clinical trial and the investigational drug.
Exclusion Criteria
- •Subjects with clinically significant diseases or a history of conditions involving the digestive, cardiovascular, endocrine, respiratory, hematologic/oncologic infectious, renal/genitourinary, psychiatric/neurologic, musculoskeletal, immune, otorhinolaryngologic, dermatologic, or ophthalmologic systems.
- •Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) or gastrointestinal disease that may affect drug absorption.
- •Subjects who have taken drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose, or drugs that may interfere with this clinical trial within 10 days before the first dose
- •Subjects who have participated in another clinical trial or bioequivalence study and received an investigational drug within 6 months before the first administration.
- •Subjects who have donated whole blood or blood components within 2 weeks, or received a blood transfusion within 4 weeks before the first administration.
- •Subjects who meet any of the following criteria within 1 month before the first dose:
- •Average alcohol consumption exceeding 21 drinks/week for men
- •Average alcohol consumption exceeding 14 drinks/week for women
- •(1 drink = 50 mL soju, 30 mL liquor, or 250 mL beer)
- •Smoking more than 20 cigarettes/day on average
- •Subjects judged by the principal investigator to be unsuitable for participation in this clinical trial for any reason other than the above selection or exclusion criteria.
- •Female subjects who are pregnant, suspected of being pregnant, or lactating
Arms & Interventions
Arm A
Experimental
Intervention: treatment A (Drug)
Arm A
Experimental
Intervention: treatment C (Drug)
Arm B
Experimental
Intervention: treatment B (Drug)
Arm B
Experimental
Intervention: treatment C (Drug)
Outcomes
Primary Outcomes
AUCτ
Time Frame: 0 to 24hr
Evaluation PK
Cmax,ss
Time Frame: 0 to 24hr
Evaluation PK
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult VolunteersHealth, SubjectiveNCT05009368Celltrion41
Completed
Phase 1
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult VolunteersHealth, SubjectiveNCT05002244Celltrion37
Recruiting
Phase 1
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy SubjectsDrug Drug InteractionNCT06119958Daewoong Pharmaceutical Co. LTD.32
Completed
Phase 1
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting ConditionFastingNCT01831661IPCA Laboratories Ltd.48
Completed
Phase 1
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed ConditionFastingNCT01831674IPCA Laboratories Ltd.48